Skip to main content
. Author manuscript; available in PMC: 2021 Mar 5.
Published in final edited form as: Lancet Neurol. 2020 May;19(5):402–412. doi: 10.1016/S1474-4422(20)30078-8

Figure 2: Time to first protocol-defined relapse during the double-blind period in the overall patient cohort (A), the subgroup seropositive for aquaporin-4 antibodies (B), and the subgroup seronegative for aquaporin-4 antibodies (C).

Figure 2:

Patients who did not experience a protocol-defined relapse were censored at the end date of the double-blind period. The dashed lines represent 48 weeks, 96 weeks, and 144 weeks from baseline. The numbers within the figures represent the proportion of relapse-free patients. HR=hazard ratio. NE=not evaluable.